We have completed a phase I study to test feasibility and patients treated at each level. The second schedule toxicity of immunotherapy of hepatic metastases from colincluded multiple injections of 10 g. Three patients orectal carcinoma by direct gene transfer of HLA-B7, a received injections on days 1 and 15. Three patients MHC class I gene. Eligible patients were HLA-B7 negative, received injections on days 1, 15 and 29. A total of 15 immunocompetent by PHA lymphocyte stimulation and had patients have completed treatment. The plasmid DNA was at least two measurable hepatic lesions on CT scan for detected in 14 of 15 patients (93%) by PCR. In five of 15 measurement of response of the injected lesion, as well as patients (33%) mRNA was also detected. The HLA-B7 proevaluation of possible distant response. Under ultrasonotein was detected in five of eight patients (63%) by imgraphic guidance the hepatic lesions were injected with munohistochemistry and in seven of 14 patients (50%) Allovectin-7, a liposomal vector containing the combination tested by fluorescence activated cell sorting (FACS) analyof the HLA-B7 gene with ␤ 2 -microglobulin formulated with sis. There has been no serious toxicity directly attributable the lipid DMRIE-DOPE. Eligible patients were injected on to allovectin-7. Our results suggest that liposomal gene two schedules. On the first schedule patients received an transfer by direct injection is feasible and non-toxic. Further injection on day 1 and the injected lesion was biopsied to studies will be necessary in order to establish the theradetermine transfection every 2 weeks for 8 weeks. Doses peutic efficacy. were escalated from 10 g to 50 g to 250 g with three
Introduction compatibility MHC gene transfer was assessed in mice Colorectal adenocarcinoma, with more than 150 000 new after induction of an immune response to recombinant cases diagnosed in the USA per year and approximately murine class I MHC gene by direct gene transfer in vivo. 6, 7 60 000 deaths per year, is a major public health problem.
The same animal studies showed that uptake of recombiChemotherapy (including the standard regimen of 5-FU, nant DNA following direct gene transfer by lipid leucovorin) has marginal efficacy in the treatment of mediated transfection was not associated with autometastatic colorectal cancer, and new therapeutic immunity, toxicity, or gonadal localization. approaches are clearly needed.
Nabel and colleagues 8 treated five patients with maligTotal or selective loss of major histocompatibility nant melanoma with intratumoral injection of the HLA-(MHC) class I antigens has been reported in up to 60% B7 gene-lipid complex. In one of the patients the injected of colorectal carcinoma biopsies as well as in other solid lesion as well as distant metastases regressed. This tumors and hematologic malignancies. [1] [2] [3] Animal studies response appeared to be mediated by a CD8 + lymphohave demonstrated that expression of injected foreign cytic infiltrate. All the patients demonstrated evidence of MHC molecules can result in immunologic destruction gene transfer without evidence of toxicity related to the of the tumor 4, 5 by eliciting a T cell dependent immune treatment. response not only to the foreign MHC protein, but also
In an effort to further improve the HLA-B7 gene-lipid to previously unrecognized tumor-associated antigens.
vector, an improved lipid formulation was used and the ␤ 2 -microglobulin gene was added to the plasmid containing the HLA-B7 gene. The final product (plasmid VCL-HLA-B7 heavy chain has been inserted into a simplified enrollment had grade 1 (WHO) AST elevation (without any concomitant evidence of disease progression) at day eukaryotic expression vector so that HLA-B7 heavy chain is expressed when the plasmid is introduced into cells.
20 that persisted to day 45 (patient's last evaluation). The ␤ 2 -microglobulin gene was included to enhance the expression of the complex HLA-B7 molecule and eliminDrug-related adverse events There were no adverse events directly related to the ate a possible tumor mechanism of immunologic escape. Deletion of ␤ 2 -microglobulin gene has been described in study drug and in no instances did the administration of drug have to be discontinued. Directed ultrasound human tumors including colon cancer and leads to decreased expression of MHC-class I antigens. 9 guided biopsies of the liver as well as the injection of Allovectin-7 were well tolerated. After the drug adminisInjection of the VCL-1005 plasmid into subcutaneous B16 melanoma tumors in mice significantly slowed tumor tration, three out of 15 patients complained of soreness at the biopsy site, and one out of 15 patients experienced growth. The direct intratumoral injection of either the plasmid DNA encoding HLA-B7 and ␤ 2 -microglobulin right shoulder pain. One patient had an episode of severe anxiety associated with the drug administration. In alone, or of the cationic lipid formulation alone had no significant effect on tumor growth.
addition, one out of 15 patients had an allergic reaction to contrast dye and developed hypotension during CT In mice that received direct intrahepatic injection of the same plasmid VCL-1005/lipid combination, no adverse scanning as part of the study. effects were detected by histopathology or clinical biochemistry tests. 10 In addition, repeated i.v. injection of the Clinical responses Four of 15 patients progressed by day 29, two by day 43, plasmid in monkeys and mice proved its safety and allowed the study of its pharmacokinetics. 11 and an additional four patients by day 57. There were no objective antitumor responses in either the injected indiThese findings prompted us to evaluate the clinical applicability of VCL-1005 injection for treatment of liver cator lesion or the uninjected control lesion. Five patients remained stable. Of the 10 patients with progressive dismetastases in patients with metastatic colorectal cancer in a phase I trial looking for feasibility, toxicity, schedules, ease, nine had simultaneous progression of both the injected and uninjected lesion. One patient progressed dosing and therapeutic results.
only in the uninjected lesion. There were no deaths at the time of completion of the study, but nine of the study
Results
patients have subsequently died. Table 2 shows the change in size of the indicator lesion at the time of pro-A total of 17 patients were enrolled in the study; two gression or completion of the study (day 57), the disease were not evaluable because of their refusal to undergo status and the day of progression. biopsy on day 29. Among the evaluable patients, there were 10 men and five women with a median age of 60
Laboratory results -HLA-B7 gene transfection and years (range 38-74). The performance status was protein expression Karnofsky 90 in the majority of patients. Five out of 15 HLA-B7 gene transfection and protein expression was patients entered this study with elevated alkaline phosdetected in tumor biopsies by PCR analysis, flow cytomephatase levels, and five out of 15 patients entered the try and immunohistochemistry after intratumoral injecstudy with elevated AST. Three of 15 patients had no tion. Plasmid DNA was detected in 14 of 15 patients previous chemotherapy or radiation therapy. Table 1 (93%). In five of 14 patients the plasmid was detected summarizes the clinical data on our patient population.
until day 43 and in nine of 14 until day 57. By using RTSafety was assessed by evaluation of chemistry and PCR we detected mRNA in five of 15 patients (33%). The hematology parameters taken at scheduled intervals and HLA-B7 protein was detected by FACS in seven of 14 by the occurrence of adverse events.
patients (50%) and by immunohistochemistry in four of seven patients (57%) (Figure 1 ). There was not always Laboratory tests correlation between the RT-PCR detection of mRNA and Clinical chemistry and hematology results were not the protein detection by FACS or immunohistochemistry influenced by the administration of the study drug. Only possibly attributed to sampling variations. Generally our one out of 10 patients with normal AST at the time of methods were somewhat more sensitive in detecting protein than mRNA. Our results also indicated that the low- single injection appears to be equivalent to multiple Female 5 doses in terms of transfection (Table 3) . HLA-B7. Follow-up lost after day 57.
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Figure 1 Patient M110 liver biopsy (day 29). (a and b) Haematoxylin and eosin and keratin stains consistent with metastatic colorectal carcinoma. (c) Same biopsy sample stains (+) for HLA-B7, proving transfection. (d) Same biopsy sample showing infiltration by CD8
+ cells.
for cancer immunotherapy in the past. By using IL-2 and lymphokine activated killer (LAK) cells, Rosenberg and colleagues 12 achieved one CR and three PRs out of 30 patients with advanced colorectal cancer.
Tumor infiltrating lymphocytes (TIL) obtained from the MC-38 colorectal adenocarcinoma cell line were found specifically to lyse the tumor from which they are derived. 13 Specific cytokine release was demonstrated when these TIL were in contact with their autologous tumors 14, 15 and the preliminary results of a clinical trial using genetically modified TIL have recently been reported. 16, 17 Other studies have examined the tumor suppressive effect of lymphokine production by genetically altered tumor cells. The introduction of tumor cells transfected with an IL-2 expression vector into syngeneic mice stimulated a MHC class I restricted cytolytic T lymphocyte response which protected against subsequent rechallenge with a parental tumor cell line.
18
To address further the question of whether specific and could be achieved without toxicity. Interestingly there was also one PR manifested not only in the injected lesion, but also in distal metastatic sites proving that immune-mediated rejection of the tumor was feasible.
8
A lipid based system of in vivo gene delivery like Allo- vectors. 19 Our study showed that adverse effect events were for the most part related to the underlying disease. All of the other events associated with the injection procedure were tolerable and self-resolved. We conclude that injection of the HLA-B7-lipid complex into colorectal Discussion liver metastases is a safe and well tolerated method of in vivo gene transfer. Our study is the first clinical trial for patients with metastatic colorectal carcinoma treated by intratumoral gene
We also showed that our system had a very high transfection rate. By using PCR, we were able to detect the transfer of the HLA-B7 gene in a liposomal vector.
Colorectal adenocarcinoma has been one of the targets plasmid DNA in 93% of the patients. Also, in 33% of the patients, mRNA was detected. The transfected gene was phocyte response to phytohemagglutinin (PHA) before entry. Contraindications for treatment were active autoalso able to use the cellular mechanism for translation: HLA-B7 protein was detected in four out of seven immune disease, hepatitis, active infection, immunosuppressive therapy, surgery within the past 2 weeks, and patients tested by immunohistochemistry and in seven out of 14 patients (50%) tested by fluorescence activated radiation, chemotherapy or steroids within the past 3 weeks. All patients gave written, informed consent. cell sorting (FACS) analysis. Of note, there was no significant difference in transfection and HLA-B7 expression The protocol was approved by the Recombinant DNA Advisory Committee (RAC) of the NIH. between the different doses of Allovectin-7 used in our study. In addition, in our study Allovectin-7 was able to elicit a biological response with HLA-B7-specific cytoTreatment plan and study design The study drug VCL-1005 (Allovectin-7) was supplied by toxic lymphocytes being detected in the peripheral blood by LDA in eight out of 15 patients in the absence of any Vical (San Diego, CA, USA) in four sterile vials stored between −10°to −70°C. One vial contained the plasmid antibody response. Furthermore, it stimulated the infiltration of CD8
+ cells into the tumors as visualized by VCL-1005, with the Rous sarcoma virus long terminal repeat RSV promotor/enhancer 21 that drives transcripimmunohistochemistry of subsequent biopsies.
Despite the biological and immunological responses tion of both the MHC class I human leukocyte antigen B7 gene (HLA-B7, heavy chain) and the chimpanzee ␤ 2 -none of our patients achieved clinical response. In related phase I studies of Allovectin-7 in patients with metastatic microglobulin (light chain) gene (Figure 2 ). The plasmid preparation and purification technique has been renal cell cancer similar biological responses with no objective clinical tumor regression were observed, while described elsewhere. 10, 22 The second vial contained the lipid mixture which is a formulation of two compounds: in a cohort of advanced melanoma patients tumor shrinkage occurred in seven of 14 patients with clinical dioleoyl phosphatidyl-ethanolamine (DOPE) and (2,3-bistetradecyloxy) propyl,b-hydroxyethyl, dimethylammo-PR in four of these. 20 Although lack of susceptibility of colorectal cancer to the induced immune response could niumbromide (DMRIE) which are rapidly metabolized. When introduced into the target tumor the lipid facilihave been the reason for the lack of response, tumor burden and size of the injected lesion may also have contribtates transfection of the VCL-1005 plasmid/DMRIE-DOPE lipid mixture. In addition there were two vials of uted to the lack of clinical benefit. Our plan is to optimize these parameters in a phase II trial. Lactated Ringer's Injection Vehicle. The DNA concentration in the preparation was 1 mg/ml. The DNA-lipid In conclusion, we have demonstrated that liver metastases of colorectal cancer can be very efficiently transcomplexes were prepared immediately before administration. DNA was supplied in 1 mg/ml concentration in fected by the HLA-B7 plasmid lipid combination. Biologic response was achieved with tolerable side-effects 400 l Lactated Ringer's solution. Lipid (DMRIE-DOPE) was supplied as a dried film. Each vial was reconstituted associated wtih administration. There was no difference in transfection or biological response between the differwith 400 l Lactated Ringer's solution by vortexing until homogeneous. The content of the lipid vial was transent plasmid doses tested. We conclude that it is reasonable to proceed with phase II testing of Allovectin-7 at ferred into the DNA vial and mixed well by repeated inversion. The final concentration of the HLA-B7 plasmid the lowest effective dose (10 g) with multiple administrations, to investigate further the possibility of clinical DNA was 500 g/ml. The DNA-lipid complex was prepared within 6 h of administration. The amount of DNAresponses in patients with metastatic colorectal cancer.
lipid complex injected into each tumor was adjusted for tumor size up to a final volume of 4 ml with Lactated
Patients and methods
Ringer's Injection Vehicle, according to the tumor size. Using a 22 G spinal needle the study drug was injected Eligibility criteria included histologically confirmed hepatic metastases from primary colorectal adenocarcinoma into multiple sites within the tumor under direct sonographic visualization. Before injection and following the beyond surgical cure. Patients had at least two liver metastases that were measurable in two dimensions on complacement of the needle, gentle aspiration was applied to the syringe to assure that no material was injected intraputed tomographic (CT) scan, one of which measured at least 2 cm in greatest diameter and was accessible for venously. Vital signs were measured before and every 15 min after the injection for at least 2 h or until the patient intralesional injection. The second measurable lesion was to serve as a control allowing for evaluation of a distant was stable. Every patient was observed for 48 h after the injection in our General Clinical Research Center (GCRC), response. All patients had either prior standard therapies for their disease and were unresponsive to them or had and a blood sample was obtained before dismissal to check serum enzymes, blood chemistries, and hemamade the decision to delay or refuse standard chemotherapy. All patients were older than 18 years, had tology values. All toxicities were graded according to WHO classification. acceptable bone marrow function (WBC Ͼ3 × 10 9 /l, and platelet count у100 × 10 9 /l), normal serum direct biliruThe patients participating in the study were divided into five groups, each consisting of three patients. The bin, AST and alkaline phosphatase not greater than three times above the upper limits of normal, serum creatinine patients in group A1 received 10 g of Allovectin-7 on day 1, while the patients in group A2 and A3 received Ͻ125% of upper limit of normal, prothrombin time р1 s above control, baseline Karnofsky performance score of 50 and 250 g of allovectin-7 on day 1, respectively. All three patients at each escalation of schedule A were at least 70 (ECOG 0, 1), and estimated life expectancy of at least 12 weeks. All patients had HLA typing before the observed for toxicity and response for 30 days before patients received Allovectin-7 at the next planned higher study and had to be HLA-B7 negative to be eligible for entry. They also had to be HBsAg, and HIV antibody dose. If responses were seen, patients were eligible for a repeat treatment. Schedule B was initiated after all three negative. All eligible patients had normal in vitro lym-patients given 50 g DNA were observed without tox-GGGAGGGGCAAACAACAGAT3′) of the HLA-B7 plasmid. The ␤ 2 -microglobulin primer corresponds to bases icity. Patients in group B1 received two injections of 10 g of Allovectin-7 with the second injection 2 weeks after 35-37 of the sequence deposited in GenBank under accession number J00105. Samples were analyzed by ethithe first. Patients in group B2 received three injections of 10 g with injections spaced 2 weeks apart. After a month dium bromide staining on a 1.5% agarose gel for the expected 549 bp PCR (DNA) or 397 bp RT-PCR of observation responding patients were eligible for repeat treatment.
(mRNA) product.
Treatment assessment FACS analysis and immunohistochemistry to detect the Pretreatment evaluation included physical examination, presence of the recombinant gene product in biopsy chest radiography, EKG, hematology and chemistry samples: groups, delayed hypersensitivity skin tests, and i.v. con-(1) Flow cytometric analysis: Tumor biopsies were digested trast enhanced CT of the liver for measurements of the in collagenase at 37°C for 30 min or until a single cell lesion to be injected and the control lesion. Patients were suspension was achieved. Cells were pelleted, subsequently evaluated by a study investigator for overwashed, resuspended and viability was determined all disease status and treatment response every 2 weeks by Trypan blue dye exclusion. Cells were divided for a total of 8 weeks. Hematology and chemistry group into three equal quantities for staining with (1) FITCas well as a prothrombin time and an activated thrombolabelled anti-mouse IgG (Sigma, St Louis, MO, USA); plastin time were performed during those visits. Biopsy (2) BB7.1 mAb (American Type Culture Collection) of the injected lesion was performed at 2, 4, 6 and 8 weeks directed against human HLA-B7 counterstained with from injection, and follow-up CT scans were performed FITC-labelled anti-mouse IgG (Sigma); and (3) Biotin before the biopsy on biopsy days. Blood samples were labelled HLA-A,B,C (Becton Dickinson, San Jose, CA, also collected to be screened for antibodies against HLA-USA) antibody (directed against human MHC class I) B7 DNA or protein. After the completion of the study, and counterstained with avidin-FITC. Samples were the patients were followed every 8 weeks until profixed in 1% paraformaldehyde and 20 000 events per gression and then every 8 to 12 weeks.
histogram (when possible) were analyzed on a Becton Complete regression (CR) was defined as a total disapDickinson FACScan-plus flow cytometer. Samples pearance of all evidence of tumor. Partial regression (PR)
were considered positive if у8% of the cells were was defined as more than 50% reduction of the product positive for HLA-B7 (above background staining). of the two perpendicular diameters of the indicator lesion (2) Immunohistochemical staining: Snap frozen tissue secseen on the CT scan. Progression was defined as an tions were stained for tumor infiltrating T cells (CD8 increase in size of the indicator lesion by at least 25% or and CD4; Becton Dickinson) and HLA-B7 antigen as the appearance of new lesions. Patients not meeting (BB7.1 mAb) utilizing a standard immunohistochemcriteria for CR, PR or progression were defined as stable.
ical method on an automated instrument (Ventana Medical Systems, Tucson, AZ, USA) as previously Laboratory evaluation of transfection described. 23 Tumor infiltrating T cells were judged on a relative scale (0-4+) based on microscopic inspec-PCR analysis of tumor cells in biopsy to confirm the prestion of T cells at the site of keratin reactivity. HLAence of plasmid DNA and mRNA in the tumor: Genomic B7 was judged as absent or present (1+ to 4+) based DNA and total RNA were isolated from the same core on signal presence or absence in the neoplastic cells needle biopsy material using TRIZOL (Gibco BRL, Life judged on microscopy. Isotype-matched irrelevant Technologies, Gaithersburg, MD, USA). Oligonucleotide antibodies were used as negative controls for all primers were synthesized corresponding to the RSV proassays. Positive controls included: (1) a same slide moter (sense 5′GGGAGGGGGAAATGTAGTCCTA3′) normal tonsil for CD8 + and CD4; (2) cytospin concenand the human HLA-B7 (anti-sense, 5′TGTGTTCCGGTC tration (Ficoll-Hypaque separation) of known HLA-CCAATACTC3′). The HLA-B7 primer corresponds to B7 positive blood lymphocytes. bases 251-272 of the sequence deposited in GenBank under accession number M6102. PCR was performed FACS analysis for circulating antibodies to HLA-B7 (anti using 1-200 ng of genomic DNA for 45 cycles of denatur-HLA-B7 Abs): Thawed, centrifuged, and heat-inactivated ation (94°C, 4 min), annealing (60°C, 30 s) and extension patient plasma was incubated with HLA-B7 positive peri-(75°C, 30 s) in a programmable thermal controller (MJ pheral blood lymphocytes (PBLs) for 30 min before stainResearch, Watertown, MA, USA) using an in-sample ing with anti-mouse Ig-FITC or anti-human Ig-FITC probe. Sensitivity was determined by dilutional analysis (Sigma). After washing and fixing cells in 1% paraformaland was estimated at one copy of plasmid DNA. For RTdehyde, 20 000 cells per histogram were analyzed on a PCR, approximately 0.1-1 g of total RNA was treated Becton Dickinson FACScan-plus flow cytometer. Positive with DNase I (Gibco BRL, Life Technologies) and then controls consisted of staining with hyperimmune anticDNA synthesized using the cDNA Cycle Kit (Invitrogen, HLA-B7 sera, while normal plasma and time 0 patient San Diego, CA, USA). cDNA synthesis was primed with plasma were used as negative controls. oligo-dT using the cDNA Cycle Kit (cat K1310-02; Invitrogen). PCR analysis of the synthesized cDNA was performed using 45 cycles of denaturation (94°C, 4 min),
LDA to evaluate alterations of the frequency of HLA-B7 specific CTL, LAK and NK cells in the peripheral blood annealing (58°C, 30 s) and extension (75°C, 30 s). Primers corresponded to the ␤ 2 -microglobulin (sense, 5′TCCAGC
following gene transfer: The frequency of cytotoxic effector cell precursors was assessed by limiting dilution assay GTACTCCAAAGATTCAG3′) region and the bovine growth hormone (BGH) terminator region (antisense, 5′G
(LDA) as previously described. 24 Briefly, a cell dose
